文献速递艾滋病与性传播感染

妊娠晚期埃替拉韦暴露显著降低:PANNA网络药代动力学数据

Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该4期研究纳入14名HIV-1感染孕妇,评估妊娠对埃替拉韦/考比司他药代动力学的影响。结果显示妊娠期埃替拉韦停药间期谷浓度(Ctrough)降低77%,85%孕妇Ctrough低于有效浓度(EC90),支持妊娠期避免使用埃替拉韦/考比司他的推荐。

要点

  • 妊娠期埃替拉韦Ctrough降低77%,85%孕妇低于EC90。
  • 研究结果支持妊娠期避免使用埃替拉韦/考比司他。
  • 该结论来自14名HIV-1感染孕妇的药代动力学数据。

核心结论

  • 妊娠期使用埃替拉韦/考比司他导致埃替拉韦暴露显著降低,支持妊娠期避免该方案的推荐。

研究设计与样本

  • 4期药代动力学研究,纳入14名HIV-1感染孕妇,来自PANNA网络。

主要发现

  • 妊娠期埃替拉韦停药间期谷浓度(Ctrough)降低77%。
  • 85%的孕妇埃替拉韦Ctrough低于有效浓度(EC90)。

关键数值与推荐

  • 埃替拉韦Ctrough降低77%,85%孕妇Ctrough低于EC90。

临床怎么用

  • 临床应避免在妊娠期使用埃替拉韦/考比司他方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the end of the dosing interval (Ctrough) was reduced by 77%, with 85% of pregnant women having a Ctrough below the effective concentration (EC90). Clinical Trials Registration. NCT00825929.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Bukkems V, Necsoi C, Tenorio CH, et al. Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network. Clin Infect Dis. 2020. PMID: 32330231. doi:10.1093/cid/ciaa488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。